Valuation : Ovid Therapeutics Inc.

Market Cap 547M 471M 442M 403M 760M 52.26B 762M 5.24B 2.05B 26.38B 2.05B 2.01B 87.48B P/E 2026 *
-7.43x
P/E 2027 * -6.78x
Enterprise Value 547M 471M 442M 403M 760M 52.26B 762M 5.24B 2.05B 26.38B 2.05B 2.01B 87.48B EV / Sales 2026 *
651x
EV / Sales 2027 * 2,449x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ovid Therapeutics Inc.

1 day-4.44%
Current month+26.13%
1 month+22.27%
3 months+2.56%
6 months+71.78%
Current year+71.78%
1 week 2.67
Extreme 2.67
2.95
1 month 2.2
Extreme 2.2
2.95
Current year 1.36
Extreme 1.36
3.1
1 year 1.12
Extreme 1.12
3.1
3 years 0.24
Extreme 0.2425
4.1
5 years 0.24
Extreme 0.2425
4.14
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Free

Chief Financial Officer

50,000 0.0268%
6/7/26 Other

Chief Financial Officer

450,625 0.2414%
7/4/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-4.44%0.00%+118.75%-26.12% 547M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -2.26%-1.73%+63.87%+169.76% 28.25B
Weighted average by Cap. -1.94%-1.50%+53.85%+151.17%

Financials

2026 *2027 *
Net sales 841K 724K 679K 620K 1.17M 80.34M 1.17M 8.06M 3.14M 40.56M 3.16M 3.09M 134M 223K 192K 180K 165K 310K 21.34M 311K 2.14M 835K 10.77M 838K 820K 35.72M
Net income -68.63M -59.14M -55.45M -50.62M -95.35M -6.56B -95.66M -658M -257M -3.31B -258M -252M -10.98B -83.53M -71.98M -67.49M -61.6M -116M -7.98B -116M -801M -312M -4.03B -314M -307M -13.36B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
28/08/26 US$2.800 -4.44% 1,673,900
27/08/26 US$2.930 +1.74% 1,723,280
26/08/26 US$2.880 -1.03% 1,143,484
25/08/26 US$2.910 +3.19% 1,449,582
24/08/26 US$2.820 +0.71% 1,230,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.800USD
Average target price
5.693USD
Spread / Average Target
+103.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock